News | Simon van der Pol

3 min read

Next-generation COVID-19 vaccine mRNA-1283 is a cost-effective investment for older and high-risk adults in the Netherlands

Simon van der Pol: 21 September 2026, 16:27:08 CEST

A new cost-effectiveness analysis finds that the next-generation vaccine mRNA-1283 could prevent thousands more hospitalisations and deaths than the vaccine currently used in the Netherlands, at a price the Dutch healthcare system can justify.

Vaccination COVID-19 Cost-effectiveness analysis

2 min read

What Delayed RSV Vaccination Is Costing the Netherlands

Simon van der Pol: 2 June 2026, 14:06:53 CEST

Every winter, the Respiratory Syncytial Virus (RSV) fills hospital wards. Around 6,000 older adults are admitted with RSV infection in the...

RSV Societal Cost-Benefit Analysis Vaccination

1 min read

Launch of the vaccination guideline for adults with chronic lung disease

Simon van der Pol: 25 September 2025, 13:25:48 CEST

On World Lung Day, the Long Alliantie Nederland introduced the first national vaccination guideline for adults with chronic lung disease. Developed...

Public Health Infectious Disease RSV Chronic Lung Diseases Vaccination Pneumococcal COVID-19 Influenza

1 min read

Health-Ecore joins €1.8M DELPHI project to advance personalized lung cancer treatment

Simon van der Pol: 2 September 2025, 00:00:00 CEST

We’re proud to announce that Health-Ecore is a key partner in the newly launched DELPHI project, a €1.8 million initiative aimed at transforming lung...

Start-ups Oncology Diagnostics

1 min read

RSV immunization for children

Simon van der Pol: 21 May 2025, 00:00:00 CEST

Read our newly published paper on an RSV immunization programme for the Netherlands.

Public Health Infectious Disease RSV